Back

Dual antiplatelet therapy (DAPT) during the first 90 days post-randomisation in OCEANIC-STROKE: participant characteristics and interaction with asundexian

31 August 2026 (13:15 - 13:30)
Organised by: Logo
Congress Presentation Part of: Advances in stroke prevention: anticoagulation, antiplatelet therapy and left atrial appendage closure Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Mukul Sharma

Population Health Research Institute, Hamilton (Canada)

3 More presentations in this session

Presentation thumbnail
Half-Dose Anticoagulation versus Standard Antiplatelet Therapy for Preventing Silent Cerebral Embolism After Left Atrial Appendage Occlusion: The HALO-SCE Randomized Trial
Professor J. Weizhu (Nanjing, CN)
Slides Video
Presentation thumbnail
Sex-Specific Outcomes of Left Atrial Appendage Closure Versus Medical Therapy: The CLOSURE-AF-DZHK-16 Trial
Professor I. Eitel (Luebeck, DE)
Slides Video
Presentation thumbnail
Left Atrial Appendage Closure as an Alternative to NOAC for Stroke Prevention in Patients with Atrial Fibrillation at Low Bleeding Risk: A Patient-Level Meta-Analysis
Doctor M. Coylewright (Duluth, US)
Slides Video

Access the full session

Session thumbnail
Advances in stroke prevention: anticoagulation, antiplatelet therapy and left atrial appendage closure
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Asundexian edges out milvexian: superior stroke reduction with safer bleeding profile in factor XIa inhibition – a network meta-analysis revolutionizing secondary prevention
29 August 2026
thumbnail
Congress Presentation
15-month results of the MASTER DAPT trial.
29 August 2022
thumbnail
Congress Presentation
PACIFIC-AMI - Efficacy and safety of factor XIa inhibitor asundexian on top of dual antiplatelet therapy after acute myocardial infarction .
28 August 2022
thumbnail
Congress Presentation
Managing stroke patients with indications for both anticoagulant and antiplatelet treatment
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources